Bristol Myers Squibb (BMY) closed at $54.20 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0 ...

The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...

AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other ...

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PRME stock, giving a Hold rating today. Terence Flynn’s ...